MBMarcelo Chiara Bertolami

Marcelo Chiara Bertolami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marcelo Chiara Bertolami has a total of 238 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gender differences in Body Adiposity and Endothelial Dysfunction in Overweight and Obese Individuals with Suboptimal Vitamin D Status

    by Marcelo Chiara Bertolami

    The article by Faria et al. explored anthropometric indices, vascular and autonomic function in obese and overweight individuals with suboptimal vitamin D status. Obesity has a significant impact on human health through multiple mechanisms. One potential mechanism involves the association between obesity and low vitamin D levels. The authors used advanced techniques to evaluate endothelial function in an overweight and obese population with suboptimal vitamin D levels. […] Gender differences in Body Adiposity and Endothelial Dysfunction in Overweight and Obese

  • Open Access

    Brazilian Guideline on Dyslipidemias and Prevention of Atherosclerosis – 2025

    by Fabiana Hanna Rached, Marcio Hiroshi Miname, Viviane Zorzanelli Rocha, André Zimerman, Fernando Henpin Yue Cesena, Andrei Carvalho Sposito, Raul Dias dos Santos, Paulo Eduardo Ballvé Behr, Henrique Tria Bianco, Renato Jorge Alves, et al.


  • Open Access

    Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025

    by Fabiana Hanna Rached, Marcio Hiroshi Miname, Viviane Zorzanelli Rocha, André Zimerman, Fernando Henpin Yue Cesena, Andrei Carvalho Sposito, Raul Dias dos Santos, Paulo Eduardo Ballvé Behr, Henrique Tria Bianco, Renato Jorge Alves, et al.


  • Open Access

    The Influence of Primary Atherosclerotic Diseases on the Occurrence of Secondary Disease

    by Marcelo Chiara Bertolami

    Atherosclerosis is a chronic inflammatory process in which the accumulation of cholesterol-laden plaque restricts blood flowin the arterial vasculature. The occlusion of arteries by expanding plaque or emboli from plaque rupture or erosion underlies a variety of cardiovascular diseases including myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral vascular disease. Although cardiovascular disease remains a leading cause of morbidity and mortality in high-income countries, an epidemiological shift has occurred in recent decades., Improvements in vaccination and treatment of infectious diseases have [...] Atherosclerosis is a chronic inflammatory process in which the accumulation of cholesterol-laden plaque restricts blood flowin the arterial vasculature. The occlusion of arteries by expanding plaque or emboli from plaque rupture or erosion underlies a variety of cardiovascular diseases including myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral vascular disease. Although cardiovascular disease remains a leading cause of morbidity and mortality in high-income countries, an epidemiological shift has occurred in recent decades., Improvements in vaccination and treatment of infectious diseases have

  • Open Access

    Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021

    by Maria Cristina de Oliveira Izar, Viviane Zorzanelli Rocha Giraldez, Adriana Bertolami, Raul Dias dos Santos, Ana Maria Lottenberg, Marcelo Heitor Vieira Assad, José Francisco Kerr Saraiva, Ana Paula M. Chacra, Tania L. R. Martinez, Luciana Ribeiro Bahia, et al.

    Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um [...] Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um


  • Genomics, epigenomics and pharmacogenomics of familial hypercholesterolemia (FHBGEP): A study protocol

    by Jéssica Bassani Borges, Victor Fernandes de Oliveira, Glaucio Monteiro Ferreira, Bruna Los, Thais Kristini Almendros Afonso Barbosa, Elisangela da Silva Rodrigues Marçal, Carolina Dagli-Hernandez, Renata Caroline Costa de Freitas, Raul Hernandes Bortolin, Augusto Akira Mori, et al.


  • Open Access

    Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021

    by Maria Cristina de Oliveira Izar, Ana Maria Lottenberg, Viviane Zorzanelli Rocha Giraldez, Raul Dias dos Santos, Roberta Marcondes Machado, Adriana Bertolami, Marcelo Heitor Vieira Assad, José Francisco Kerr Saraiva, André Arpad Faludi, Annie Seixas Bello Moreira, et al.

    Lista de Siglas ACC – American College of Cardiology Acetil-CoA – acetilcoenzima A […] Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021 Lista de Siglas ACC – American College of Cardiology Acetil-CoA – acetilcoenzima A […] Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021


  • Open Access

    Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity

    by Jose Carlos de Lima-Junior, Vitor W.M. Virginio, Filipe A. Moura, Adriana Bertolami, Marcelo Bertolami, Otavio R Coelho-Filho, Ilaria Zanotti, Wilson Nadruz, Eliana Cotta de Faria, Luiz Sergio F. de Carvalho, et al.

    Objective: Obesity-related decline in high-density lipoprotein (HDL) functions such as cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction may contribute for atherogenesis among obese patients. Besides, potentially other HDL protective actions may be affected with weight gain and these changes may occur even before the obesity range. Methods: Lipid profile, body mass index (BMI), biochemical measurements, and carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899 asymptomatic individuals. HDL functions were measured in a subgroup (n=101). Results: Individuals with increased HDL-C had an attenuated increase in cIMT with elevation of BMI. CEC, HDL-C, HDL size and HDL-antioxidant activity were negatively associated with cIMT. BMI was inversely associated with HDL-mediated inhibition of platelet aggregation and CEC, but surprisingly it was directly associated with the antioxidant activity. Thus, even in non-obese, non-diabetic individuals, increased BMI is associated with a wide change in protective functions of HDL, reducing CEC and increasing antioxidant activity. In these subjects, decreased HDL concentration, size or function are related to increased atherosclerotic burden. Conclusion: Our findings demonstrate that in non-obese, non-diabetic individuals, the increasing values of BMI are associated with impaired protective functions of HDL and concomitant increase in atherosclerotic burden.

  • Open Access

    Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)

    by Marcello Casaccia Bertoluci, Rodrigo Oliveira Moreira, André Faludi, Maria Cristina Izar, Beatriz D. Schaan, Cynthia Melissa Valerio, Marcelo Chiara Bertolami, Ana Paula Chacra, Marcus Vinicius Bolivar Malachias, Sérgio Vencio, et al.

    Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.


  • Open Access

    A40850

    by Jose C. Lima, Adriana Bertolami, Riobaldo M.R. Cintra, Daniel Branco de Araujo, Henri P. Zats, Rodrigo M. Goncalves, Yara Najamura, Martha L. Sulzbach, Andre Faludi, Marcelo C. Bertolami, et al.